Related Experiment Video
Updated: May 5, 2026

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
PAR-1 Expression in Chronic Subdural Hematoma: Potential Association with Vascular Permeability
Wataru Shimohigoshi1,2,3, Hajime Takase4,5, Hiromichi Iwashita6
1Department of Neurosurgery, Yokohama City University Medical Center, Yokohama, Japan.
Chronic subdural hematoma (CSDH) is a common neurosurgical disease in the elderly, characterized by inflammation, neovascularization, and increased vascular permeability. Although protease-activated receptor-1 (PAR-1) is known to regulate vascular permeability and is implicated in chronic inflammatory diseases, its role in CSDH remains unclear. In this exploratory study, we investigated PAR-1 expression in the dura mater and outer membrane of patients with CSDH compared with controls. Age- and sex-matched cases (six CSDH, five controls) were selected for analysis. Immunohistochemistry for PAR-1 and zonula occludens-1 (ZO-1), along with mRNA expression analysis, were performed. Histologically, the outer membrane of CSDH exhibited cellular clustering and strong PAR-1 immunoreactivity in vascular structures, whereas the dura mater from both groups showed no significant PAR-1 staining. ZO-1 expression was preserved in the vasculature of the outer membrane in CSDH and the dura mater of both groups. mRNA analysis revealed a trend toward higher PAR-1 and lower ZO-1 expression in CSDH, though not statistically significant. The group effect (p = 0.24, analysis of covariance [ANCOVA] t-test) represents the adjusted difference in ZO-1 expression between CSDH and control groups after accounting for PAR-1 levels. The main effect of PAR-1 (p = 0.15, ANCOVA t-test) reflects the overall association between PAR-1 and ZO-1 expression across samples. This study provides the first evidence of PAR-1 expression in the outer membrane of CSDH, suggesting a role in promoting local vascular hyperpermeability. These findings highlight PAR-1 as a possible biomarker and therapeutic target in CSDH. Further studies with larger cohorts and quantitative analyses are warranted to clarify the molecular mechanisms underlying vascular dysfunction in CSDH.
Chronic subdural hematoma (CSDH) is a common neurosurgical disease in the elderly, characterized by inflammation, neovascularization, and increased vascular permeability. Although protease-activated receptor-1 (PAR-1) is known to regulate vascular permeability and is implicated in chronic inflammatory diseases, its role in CSDH remains unclear. In this exploratory study, we investigated PAR-1 expression in the dura mater and outer membrane of patients with CSDH compared with controls. Age- and sex-matched cases (six CSDH, five controls) were selected for analysis. Immunohistochemistry for PAR-1 and zonula occludens-1 (ZO-1), along with mRNA expression analysis, were performed. Histologically, the outer membrane of CSDH exhibited cellular clustering and strong PAR-1 immunoreactivity in vascular structures, whereas the dura mater from both groups showed no significant PAR-1 staining. ZO-1 expression was preserved in the vasculature of the outer membrane in CSDH and the dura mater of both groups. mRNA analysis revealed a trend toward higher PAR-1 and lower ZO-1 expression in CSDH, though not statistically significant. The group effect (p = 0.24, analysis of covariance [ANCOVA] t-test) represents the adjusted difference in ZO-1 expression between CSDH and control groups after accounting for PAR-1 levels. The main effect of PAR-1 (p = 0.15, ANCOVA t-test) reflects the overall association between PAR-1 and ZO-1 expression across samples. This study provides the first evidence of PAR-1 expression in the outer membrane of CSDH, suggesting a role in promoting local vascular hyperpermeability. These findings highlight PAR-1 as a possible biomarker and therapeutic target in CSDH. Further studies with larger cohorts and quantitative analyses are warranted to clarify the molecular mechanisms underlying vascular dysfunction in CSDH.

